No Data
No Data
No Data
Ted Pharmaceuticals has submitted an IPO application to the Hong Kong Stock Exchange main board.
According to the disclosure of the Hong Kong Stock Exchange on May 31, TaiDe Pharmaceuticals (Zhejiang) has submitted an application for listing on the Main Board of the Hong Kong Stock Exchange, with Morgan Stanley and Citic Securities as joint sponsors. According to the data of Frost & Sullivan, the company is the world's third largest contract research, development and production organization (CRDMO) focusing on peptides in terms of sales revenue in 2023. In terms of finance, the company recorded RMB 282 million, RMB 351 million and RMB 337 million in revenue in 2021-2023, with corresponding net profits of RMB 80.278 million, RMB 53.98 million and RMB 48.905 million during the same period.
New Stock Alert: Ted Pharmacy files for listing on the Hong Kong Stock Exchange Main Board. The company is the world's third largest institution dedicated to contracted research, development, and production of peptides.
According to Hong Kong Stock Exchange's disclosure on May 31st, Taide Medicine (Zhejiang) Co., Ltd. (hereinafter referred to as Taide Medicine) submitted its application to the Main Board of the Hong Kong Stock Exchange. The joint sponsors are Morgan Stanley and Citic Securities.
No Data
No Data